Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04488003
Title Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors BioMed Valley Discoveries, Inc
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST